Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNAI3 | P08754 | 1/20 | 0.76 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.76 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.76 |
| ▸ | DPP7 | Q9UHL4 | 4/20 | 0.68 |
| ▸ | RRM1 | P23921 | 1/20 | 0.66 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.50 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.50 |
| ▸ | CHRNB2 | P17787 | 4/20 | 0.49 |
| ▸ | CHRNB4 | P30926 | 4/20 | 0.49 |
| ▸ | CHRNA3 | P32297 | 4/20 | 0.49 |
| ▸ | CHRNA4 | P43681 | 4/20 | 0.49 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.49 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.48 |
| ▸ | GRIN2A | Q12879 | 2/20 | 0.48 |
| ▸ | GRM1 | Q13255 | 2/20 | 0.48 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.48 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.48 |
| ▸ | GRIA1 | P42261 | 2/20 | 0.47 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.47 |
| ▸ | CHRNG | P07510 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10033856 | 1.00 | GNAI3 (0.76) | GNAI3GNAO1GNAI1DPP7RRM1 | |
| SCHEMBL17345951 | 0.97 | GNAI3 (0.81) | GNAI3GNAO1GNAI1DPP7RRM1 | |
| SCHEMBL19407832 | 0.96 | GNAI3 (0.83) | GNAI3GNAO1GNAI1DPP7RRM1 | |
| SCHEMBL19402067 | 0.96 | GNAI3 (0.83) | GNAI3GNAO1GNAI1DPP7RRM1 | |
| SCHEMBL10033860 | 0.96 | GNAI3 (0.83) | GNAI3GNAO1GNAI1DPP7RRM1 | |
| SCHEMBL12085596 | 0.96 | GNAI3 (0.83) | GNAI3GNAO1GNAI1DPP7RRM1 | |
| SCHEMBL12085594 | 0.96 | GNAI3 (0.83) | GNAI3GNAO1GNAI1DPP7RRM1 | |
| SCHEMBL19407777 | 0.96 | GNAI3 (0.83) | GNAI3GNAO1GNAI1DPP7RRM1 | |
| SCHEMBL10033861 | 0.96 | GNAI3 (0.83) | GNAI3GNAO1GNAI1DPP7RRM1 | |
| SCHEMBL14048412 | 0.95 | DPP7 (0.73) | GNAI3GNAO1GNAI1DPP7RRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170290788-A1 | PHARMACEUTICAL FOR ORAL DELIVERY COMPRISING MGBG AND METHODS OF TREATING DISEASE | PATHOLOGICA, LLC | 2017-10-12 | — | — | US | disclosed |
| US-9616035-B2 | Pharmaceutical for oral delivery comprising MGBG and methods of treating disease | PATHOLOGICA, LLC (US) | 2017-04-11 | — | — | US | disclosed |
| US-20150359761-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF DEMYELINATING DISEASES | PATHOLOGICA, LLC | 2015-12-17 | — | — | US | disclosed |
| WO-2014110154-A1 | METHODS AND COMP0STIONS FOR TREATMENT OF DEMYELINATING DISEASES | PATHOLOGICA LLC (US) | 2014-07-17 | — | — | WO | disclosed |
| US-20140051765-A1 | PHARMACEUTICAL FOR ORAL DELIVERY COMPRISING MGBG AND METHODS OF TREATING DISEASE | PATHOLOGICA LLC (US) | 2014-02-20 | — | — | US | disclosed |
| US-20120289604-A1 | PHARMACEUTICAL FOR ORAL DELIVERY COMPRISING MGBG AND METHODS OF TREATING DISEASE | PATHOLOGICA LLC (US) | 2012-11-15 | — | — | US | disclosed |
| US-8258186-B2 | Pharmaceutical for oral delivery comprising MGBG | PATHOLOGICA, LLC (US) | 2012-09-04 | — | — | US | disclosed |
| US-20110112199-A1 | PHARMACEUTICAL FOR ORAL DELIVERY COMPRISING MGBG AND METHODS OF TREATING DISEASE | PATHOLOGICA LLC (US) | 2011-05-12 | — | — | US | disclosed |
| WO-2011009039-A2 | PHARMACEUTICAL FOR ORAL DELIVERY COMPRISING MGBG AND METHODS OF TREATING DISEASE | PATHOLOGICA LLC (US) | 2011-01-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150359761-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF DEMYELINATING DISEASES | SRM, PMP22, SMS | GNAI3 3495/4885GNAO1 2482/4885GNAI1 3381/4885 |
| US-20140051765-A1 | PHARMACEUTICAL FOR ORAL DELIVERY COMPRISING MGBG AND METHODS OF TREATING DISEASE | BPGM, PYGB, EDNRB | GNAI3 1090/4885GNAO1 703/4885GNAI1 630/4885 |
| US-20170290788-A1 | PHARMACEUTICAL FOR ORAL DELIVERY COMPRISING MGBG AND METHODS OF TREATING DISEASE | BPGM, PYGB, EDNRB | GNAI3 1090/4885GNAO1 703/4885GNAI1 630/4885 |
| US-20120289604-A1 | PHARMACEUTICAL FOR ORAL DELIVERY COMPRISING MGBG AND METHODS OF TREATING DISEASE | BPGM, PYGB, EDNRB | GNAI3 1090/4885GNAO1 703/4885GNAI1 630/4885 |
| US-20110112199-A1 | PHARMACEUTICAL FOR ORAL DELIVERY COMPRISING MGBG AND METHODS OF TREATING DISEASE | BPGM, PYGB, EDNRB | GNAI3 1090/4885GNAO1 703/4885GNAI1 630/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.